Insider buying last 90 days
No open-market insider purchases were filed for PAHC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every PAHC insider filing, plotted on the chart in Gekko.Open PAHC in Gekko
NASDAQ: PAHC
Phibro Animal Health (PAHC) Stock Analysis & Forecast
Oct 12 close
$37.43−0.87 (−2.3%)
Gekko Brief
Oct 12 closePhibro Animal Health closed at $37.43 on 12 October 2026, -2.3% on the day. The price sits between the 50-day ($35.98) and 200-day ($41.27) moving averages, inside a 52-week range of $28.25 to $60.08. The GekkoIndex reads 51.2, in the Neutral zone, down 0.1 points over five sessions. Gekko Fair Value is $39.18, so the price is 4.5% below it.
The next earnings report is due on 4 November 2026, 23 days away (before open). Over the last 8 reports the company beat the earnings estimate 8 times, with an average move of 12.2% across the report. Seasonally, the next 20 trading days from this point averaged +7.3% over the last 5 years, rising in 4 of them.
2 firms rate the stock: 1 buy, 0 hold and 1 sell, with a consensus target of $44.00. A typical daily move is about 3.8%, and a typical 20-day move about 7%. On the swing-trade checklist, 1 item reads supportive and 1 reads as a headwind (earnings risk).
A plain summary of the figures as of the Oct 12, 2026 close.
Phibro Animal Health price vs fair value
Close $37.43200-day averageGekko Fair Value $39.18
Phibro Animal Health quick facts
- Market cap
- $1.52B
- P/E ratio
- 15.4
- Forward P/E
- 13.8
- EPS, TTM
- $2.43
- Revenue, TTM
- $1.52B
- Profit margin
- 6.6%
- Dividend yield
- 1.27%
- Beta
- 0.42
- Volume
- 205,850 avg 244,026
- 1-year return
- +0.7%
- Typical daily move
- ±3.8%
- Typical 20-day move
- ±7%
- 50-day average
- $35.98
- 200-day average
- $41.27
- Next earnings
- Nov 4 before open
- Shares outstanding
- 21.11M
Phibro Animal Health swing-trade checklist
Phibro Animal Health scores 1 supportive, 3 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive3 mixed1 headwind
- Trendmixed
Averages disagree
Close $37.43 sits between the 50-day ($35.98) and 200-day ($41.27) averages, or the averages disagree.
See the chart - GekkoIndexmixed
51.2, Neutral
Reading 51.2 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
4.5% below
Price is within 5% of Gekko Fair Value (4.5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+7.3% on average
From this point in the calendar, the next 20 trading days averaged +7.3% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Phibro Animal Health stock chart and price history
Phibro Animal Health closed at $37.43 on Oct 12, 2026, +0.7% over the past year, inside a 52-week range of $28.25 to $60.08.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +5.1%
- 3 months
- +13.3%
- 6 months
- −37.2%
- 1 year
- +0.7%
The full PAHC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PAHC in Gekko
Follow Phibro Animal Health through every session
Put PAHC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PAHC in GekkoFree for 7 days. No credit card required.
Phibro Animal Health GekkoIndex: the smart money zone
Phibro Animal Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.2, in the Neutral zone, down 0.1 points over five sessions.
51.2Neutral
Down 0.1 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 27 | −1.5% | +9.9% | ||
| Accumulation | 173 | +2.0% | +6.7% | ||
| Neutral (current zone) | 415 | +1.1% | +4.8% | ||
| Distribution | 60 | +0.5% | −1.1% | ||
| Selling | 7 | Too few readings yet | |||
Average PAHC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the PAHC price, zone by zone.Track PAHC in Gekko
Is Phibro Animal Health stock overvalued? Gekko Fair Value
Phibro Animal Health trades 4.5% below Gekko Fair Value of $39.18, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Phibro Animal Health shares are worth, recalculated every trading day.
$39.18
Gekko Fair Value, Oct 10, 2026
4.5% below fair value · About fair value
At the end of Aug 2026 the price was 8.5% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open PAHC in Gekko
Phibro Animal Health insider and Congress trading
No open-market insider purchases were filed for Phibro Animal Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in PAHC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for PAHC, plotted on the chart in Gekko.Open PAHC in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds PAHC.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Phibro Animal Health earnings: next date and track record
Phibro Animal Health reports on Nov 4, 2026, before the open (23 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 23 days away
- EPS estimate
- $0.76
- Revenue estimate
- $381.7M
8 of 8reports beat the EPS estimate
±12.2%average move across the report
7 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 26, 2026 AI summary
- What they said
- PAHC reported record fiscal 2026 net sales exceeding $1.5 billion with adjusted EBITDA rising 39% to $255 million. Q4 sales grew 5% and adjusted EBITDA grew 29%. Legacy Animal Health grew 8% in Q4 and 7% for the full year, while Mineral Nutrition surged 20% in Q4. The acquired Zoetis MFA portfolio grew 70% for the full year despite an 11% Q4 decline. PAHC is closing its Chicago Heights facility to optimize its manufacturing network.
- Guidance
- Management provided fiscal year 2027 guidance ending June 30, 2027. Phibro Forward transformation program is expected to deliver cumulative EBITDA contributions of approximately $50 million in fiscal 2027 versus the fiscal 2024 baseline, signaling continued margin improvement.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 26, 2026 | $0.85 est $0.71 | $396.7M est $381.2M | +1.2% |
| May 6, 2026 | $0.76 est $0.71 | $383.5M est $367.0M | −23.3% |
| Feb 4, 2026 | $0.87 est $0.69 | $373.9M est $355.6M | +21.0% |
| Nov 5, 2025 | $0.73 est $0.59 | $363.9M est $345.4M | +2.2% |
| Aug 27, 2025 | $0.57 est $0.52 | $378.7M est $362.4M | +17.8% |
| May 7, 2025 | $0.63 est $0.52 | $347.8M est $352.2M | +16.9% |
| Feb 5, 2025 | $0.54 est $0.40 | $309.3M est $347.0M | +11.6% |
| Nov 7, 2024 | $0.35 est $0.25 | $260.4M est $246.7M | +3.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Phibro Animal Health stock forecast and analyst price targets
Analysts’ average 12-month price target for Phibro Animal Health is $44.00, +17.6% from the last close, from 2 firms rating the stock in the last 90 days.
$44.00consensus 12-month target, +17.6% from the last close
Each firm’s latest rating in the last 90 days: 2 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 1 | J.P. Morgan | $55 | +46.9% |
| Aug 25 | J.P. Morgan | $58 | +55.0% |
| Jul 28 | Bank of America Securities | — | — |
+4.8%average 20-day move after past Neutral readings
+7.3%average move over the next 20 trading days in the last 5 years
±3.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Phibro Animal Health seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Phibro Animal Health averaged +7.3% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +5.3% | 4 of 5 |
| Next 10 trading days | +5.0% | 4 of 5 |
| Next 15 trading days | +4.9% | 4 of 5 |
| Next 20 trading days | +7.3% | 4 of 5 |
| Next 30 trading days | −0.4% | 3 of 5 |
For scale, PAHC’s typical 20-trading-day move in either direction is about 7%.
Phibro Animal Health market cap and key statistics
Phibro Animal Health’s market cap is $1.52B, with a P/E ratio of 15.4 and revenue of $1.52B over the last twelve months.
Valuation
- Market cap
- $1.52B
- P/E ratio
- 15.4
- Forward P/E
- 13.8
- EPS, TTM
- $2.43
- Gekko Fair Value
- $39.18
Trading
- Volume
- 205,850
- Avg volume, 20 days
- 244,026
- 52-week high
- $60.08
- 52-week low
- $28.25
- Shares outstanding
- 21.11M
Financials
- Revenue, TTM
- $1.52B
- Profit margin
- 6.6%
- Return on equity
- 29.7%
- Quarterly earnings growth, YoY
- +24.6%
Risk and income
- Beta
- 0.42
- Typical daily move
- ±3.8%
- Typical 20-day move
- ±7%
- Dividend yield
- 1.27%
Phibro Animal Health stock news this week
1 headline about Phibro Animal Health from the past week, newest first, each linking to the publisher.
- PAHC vs. HAE: Which Stock Is the Better Value Option?Zacks Investment Research, Oct 5
Phibro Animal Health peers
Phibro Animal Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Phibro Animal Health stock FAQ
What is Phibro Animal Health’s market cap?
Phibro Animal Health’s market cap is $1.52B at the Oct 12, 2026 close of $37.43, with 21.11M shares outstanding. The shares trade on a P/E ratio of 15.4.
What is the Phibro Animal Health stock forecast?
The consensus analyst 12-month price target for Phibro Animal Health is $44.00, +17.6% from the last close. Of the 2 firms that rated the stock in the last 90 days, 1 rate it a buy, 0 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Phibro Animal Health stock overvalued or undervalued?
On Gekko’s estimate Phibro Animal Health is about fair value: the Oct 12, 2026 close of $37.43 is 4.5% below Gekko Fair Value of $39.18. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Phibro Animal Health report earnings next?
Phibro Animal Health is expected to report on Nov 4, 2026, before the market opens (23 days away). Analysts expect earnings of $0.76 per share on revenue of $381.7M. Phibro Animal Health beat the earnings estimate in 8 of its last 8 reports, moving 12.2% on average across the report.
What is Phibro Animal Health’s 52-week high and low?
Phibro Animal Health’s 52-week high is $60.08 and its 52-week low is $28.25; it closed at $37.43 on Oct 12, 2026, +0.7% over the past year.
Is Phibro Animal Health stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (seasonality), 3 as mixed (trend, gekkoindex and fair value) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Phibro Animal Health the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.